Nurix (NRIX) CFO Hans van Houte Sells Shares to Cover Taxes

What Happened

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics (NRIX), had restricted stock units (RSUs) convert into common shares and an open‑market sale was executed to cover tax withholding. The Form 4 reports conversions (acquisitions) of RSUs totaling 10,180 shares (3,750 + 2,858 + 3,572) at $0.00 per share and an open‑market sale of 2,845 shares at a weighted average price of $23.38 for proceeds of $66,524. The filing also lists related derivative disposals at $0 associated with the RSU transactions.

Key Details

• Transaction date: 2026-07-30 (filed same day).
• RSU conversions (acquisitions): 3,750; 2,858; 3,572 = 10,180 shares acquired at $0.00.
• Open‑market sale: 2,845 shares at weighted avg $23.38 = $66,524. Reported sale price range: $23.00 (low) to $23.90 (high) (footnote F2).
• Footnote F1: The sale was a mandatory "sell to cover" to satisfy tax withholding on RSU vesting — not a discretionary trade by the insider.
• Footnotes F3–F7: Each RSU converts to one share; RSUs vest 1/12 quarterly over three years (vesting schedules and first vest dates vary by grant as noted in the footnotes). RSUs do not expire (F5).
• Shares owned after the transaction: not specified in this Form 4.
• Filing timeliness: appears timely (transaction and report dated 2026-07-30).

Context

• These entries reflect RSU vesting and the common practice of selling some shares immediately to cover required tax withholding ("sell to cover"). The RSU conversions show no cash exercise cost because RSUs are rights to receive shares upon vesting (not stock options requiring cash payment). The open‑market sale was to satisfy withholding obligations and is generally considered routine administrative activity rather than an indicator of the insider’s view on the stock.